MUCODYNE

Mucodyne Adverse Events Reported to the FDA Over Time

How are Mucodyne adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Mucodyne, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Mucodyne is flagged as the suspect drug causing the adverse event.

Most Common Mucodyne Adverse Events Reported to the FDA

What are the most common Mucodyne adverse events reported to the FDA?

Hepatic Function Abnormal	29 (3.54%)
Liver Disorder	25 (3.05%)
Abnormal Behaviour	22 (2.68%)
Pyrexia	20 (2.44%)
Drug Eruption	17 (2.07%)
Rash	16 (1.95%)
Alanine Aminotransferase Increased	14 (1.71%)
Aspartate Aminotransferase Increase...	14 (1.71%)
Leukocytoclastic Vasculitis	14 (1.71%)
Stevens-johnson Syndrome	13 (1.59%)
Gamma-glutamyltransferase Increased	12 (1.46%)
	Show More
Pneumonia	12 (1.46%)
Tubulointerstitial Nephritis	12 (1.46%)
Blood Lactate Dehydrogenase Increas...	9 (1.1%)
Decreased Appetite	9 (1.1%)
Erythema Multiforme	9 (1.1%)
Erythema	8 (.98%)
Purpura	8 (.98%)
Rhabdomyolysis	8 (.98%)
Vomiting	8 (.98%)
Agranulocytosis	7 (.85%)
Allergic Granulomatous Angiitis	7 (.85%)
Anaphylactic Shock	7 (.85%)
Asthma	7 (.85%)
Cough	7 (.85%)
Depressed Level Of Consciousness	7 (.85%)
Dyspnoea	7 (.85%)
Face Oedema	7 (.85%)
Hallucination	7 (.85%)
Hepatitis Fulminant	7 (.85%)
Hypothermia	6 (.73%)
Malaise	6 (.73%)
Ocular Hyperaemia	6 (.73%)
Respiratory Failure	6 (.73%)
Somnolence	6 (.73%)
Vasculitis	6 (.73%)
Anorexia	5 (.61%)
Anxiety	5 (.61%)
Arrhythmia	5 (.61%)
Blood Alkaline Phosphatase Increase...	5 (.61%)
Blood Urea Increased	5 (.61%)
Condition Aggravated	5 (.61%)
Lymphocyte Stimulation Test Positiv...	5 (.61%)
Oedema Peripheral	5 (.61%)
Pallor	5 (.61%)
Rash Generalised	5 (.61%)
Toxic Skin Eruption	5 (.61%)
Urticaria	5 (.61%)
Aggression	4 (.49%)
Asthenia	4 (.49%)
Blood Creatine Phosphokinase Increa...	4 (.49%)
Cardiac Failure	4 (.49%)
Cerebral Haemorrhage	4 (.49%)
Convulsion	4 (.49%)
Eosinophilic Pneumonia	4 (.49%)
Hepatitis Acute	4 (.49%)
Lip Swelling	4 (.49%)
Nasopharyngitis	4 (.49%)
Oculomucocutaneous Syndrome	4 (.49%)
Pleural Effusion	4 (.49%)
Atrioventricular Block First Degree	3 (.37%)
Blood Creatinine Increased	3 (.37%)
C-reactive Protein Increased	3 (.37%)
Cerebral Infarction	3 (.37%)
Chromaturia	3 (.37%)
Crying	3 (.37%)
Epistaxis	3 (.37%)
Gait Disturbance	3 (.37%)
Gastroenteritis	3 (.37%)
Gastrointestinal Inflammation	3 (.37%)
Generalised Erythema	3 (.37%)
Haematuria	3 (.37%)
Hepatic Enzyme Increased	3 (.37%)
Hyperglobulinaemia	3 (.37%)
Hyperhidrosis	3 (.37%)
Interstitial Lung Disease	3 (.37%)
Jaundice	3 (.37%)
Mumps	3 (.37%)
Oral Mucosa Erosion	3 (.37%)
Oropharyngeal Pain	3 (.37%)
Platelet Count Decreased	3 (.37%)
Renal Failure Acute	3 (.37%)
Thrombocytopenia	3 (.37%)
Toxic Epidermal Necrolysis	3 (.37%)
White Blood Cell Count Increased	3 (.37%)
Altered State Of Consciousness	2 (.24%)
Amnesia	2 (.24%)
Anaphylactic Reaction	2 (.24%)
Anaphylactoid Reaction	2 (.24%)
Ascites	2 (.24%)
Blood Amylase Increased	2 (.24%)
Blood Pressure Decreased	2 (.24%)
Blood Sodium Decreased	2 (.24%)
Blood Urea Decreased	2 (.24%)
Chills	2 (.24%)
Coma	2 (.24%)
Conjunctival Hyperaemia	2 (.24%)
Conjunctival Oedema	2 (.24%)
Dehydration	2 (.24%)
Delirium	2 (.24%)
Diarrhoea	2 (.24%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Mucodyne, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Mucodyne is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Mucodyne

What are the most common Mucodyne adverse events reported to the FDA?

Epidermal And Dermal Conditions	95 (11.59%)
Hepatic And Hepatobiliary	78 (9.51%)
Hepatobiliary	43 (5.24%)
Respiratory	33 (4.02%)
Neurological	30 (3.66%)
Body Temperature Conditions	26 (3.17%)
Infections - Pathogen Unspecified	26 (3.17%)
Skin Vascular Abnormalities	24 (2.93%)
Psychiatric And Behavioural Symptom...	23 (2.8%)
Hematology Investigations	20 (2.44%)
Enzyme	19 (2.32%)
	Show More
Lower Respiratory Tract Disorders	16 (1.95%)
Oral Soft Tissue Conditions	16 (1.95%)
Nephropathies	15 (1.83%)
Appetite And General Nutritional	14 (1.71%)
Gastrointestinal Signs	14 (1.71%)
Allergic Conditions	13 (1.59%)
Ocular Infections, Irritations And ...	12 (1.46%)
Bronchial Disorders	10 (1.22%)
Cardiac Arrhythmias	10 (1.22%)
Disturbances In Thinking	10 (1.22%)
Renal And Urinary Tract Investigati...	10 (1.22%)
Seizures	10 (1.22%)
Urinary Tract Signs	10 (1.22%)
Muscle	9 (1.1%)
White Blood Cell	9 (1.1%)
Platelet	8 (.98%)
Central Nervous System Vascular	7 (.85%)
Vascular	7 (.85%)
Viral Infectious	7 (.85%)
Angiedema And Urticaria	6 (.73%)
Anxiety Disorders	6 (.73%)
Renal Disorders	6 (.73%)
Upper Respiratory Tract Disorders	6 (.73%)
Vascular Inflammations	6 (.73%)
Heart Failures	5 (.61%)
Pleural	5 (.61%)
Decreased And Nonspecific Blood Pre...	4 (.49%)
Deliria	4 (.49%)
Movement Disorders	4 (.49%)
Personality Disorders	4 (.49%)
Vision	4 (.49%)
Water, Electrolyte And Mineral	4 (.49%)
Fungal Infectious	3 (.37%)
Gastrointestinal Inflammatory Condi...	3 (.37%)
Hematological	3 (.37%)
Mental Impairment	3 (.37%)
Metabolic, Nutritional And Blood Ga...	3 (.37%)
Pigmentation	3 (.37%)
Protein And Chemistry Analyses	3 (.37%)
Skin Appendage Conditions	3 (.37%)
Sleep Disorders	3 (.37%)
Therapeutic And Nontherapeutic Effe...	3 (.37%)
Tongue Conditions	3 (.37%)
Bacterial Infectious	2 (.24%)
Cardiac And Vascular Investigations	2 (.24%)
Coagulopathies And Bleeding Diathes...	2 (.24%)
Electrolyte And Fluid Balance Condi...	2 (.24%)
Encephalopathies	2 (.24%)
Exocrine Pancreas Conditions	2 (.24%)
Gallbladder	2 (.24%)
Gastrointestinal	2 (.24%)
Gastrointestinal Motility And Defec...	2 (.24%)
Injuries	2 (.24%)
Musculoskeletal And Soft Tissue Inv...	2 (.24%)
Myocardial	2 (.24%)
Peritoneal And Retroperitoneal Cond...	2 (.24%)
Suicidal And Self-injurious Behavio...	2 (.24%)
Vascular Hypertensive	2 (.24%)
Administration Site Reactions	1 (.12%)
Anemias Nonhemolytic And Marrow Dep...	1 (.12%)
Bile Duct	1 (.12%)
Breast	1 (.12%)
Cardiac Disorder Signs	1 (.12%)
Changes In Physical Activity	1 (.12%)
Chemical Injury And Poisoning	1 (.12%)
Communication Disorders	1 (.12%)
Cranial Nerve Disorders	1 (.12%)
Glucose Metabolism Disorders	1 (.12%)
Headaches	1 (.12%)
Immunology And Allergy	1 (.12%)
Joint	1 (.12%)
Medication Errors	1 (.12%)
Microbiology And Serology	1 (.12%)
Musculoskeletal And Connective Tiss...	1 (.12%)
Ocular Sensory Symptoms	1 (.12%)
Ocular Structural Change, Deposit A...	1 (.12%)
Procedural And Device Related Injur...	1 (.12%)
Protein And Amino Acid Metabolism	1 (.12%)
Reproductive Tract	1 (.12%)
Skin	1 (.12%)
Sleep Disturbances	1 (.12%)
Spleen, Lymphatic And Reticulendoth...	1 (.12%)
Therapeutic Procedures And Supporti...	1 (.12%)
Thyroid Gland	1 (.12%)
Toxicology And Therapeutic Drug Mon...	1 (.12%)
Vascular Hemorrhagic	1 (.12%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Mucodyne, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Mucodyne is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.